Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1987-6-10
|
pubmed:abstractText |
Sixty-eight patients with relapsing, epithelial type ovarian carcinoma were entered into a Phase II study of vinblastine. Vinblastine was administered as a continuous intravenous infusion over five days at a starting dose of 1.7 mg/m2/day every 3 weeks. There were 44 fully evaluable and 6 partially evaluable patients. Forty-one of these patients had had only one prior treatment regimen. Grade 3 or 4 leukopenia occurred in 12 patients (24%), but Grade 3 or 4 thrombocytopenia occurred in only 2 patients. There were two clinical complete responses of 18 and 36 weeks duration and one partial response of 6 weeks for an overall response rate of 7%. We conclude that vinblastine, administered in optimal dose and schedule, has little clinical activity in previously treated patients with ovarian cancer.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0090-8258
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
27
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
214-9
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:3570059-Drug Evaluation,
pubmed-meshheading:3570059-Female,
pubmed-meshheading:3570059-Humans,
pubmed-meshheading:3570059-Leukocyte Count,
pubmed-meshheading:3570059-Liver Function Tests,
pubmed-meshheading:3570059-Ovarian Neoplasms,
pubmed-meshheading:3570059-Platelet Count,
pubmed-meshheading:3570059-Vinblastine
|
pubmed:year |
1987
|
pubmed:articleTitle |
Phase II trial of vinblastine in previously treated patients with ovarian cancer: a Southwest Oncology Group Study.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|